Capital Management Corp VA lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.3% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,911 shares of the company’s stock after selling 100 shares during the quarter. Capital Management Corp VA’s holdings in Johnson & Johnson were worth $476,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Morton Brown Family Wealth LLC boosted its position in Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock valued at $32,000 after purchasing an additional 78 shares during the period. Goodman Advisory Group LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at $39,000. Cardinal Capital Management Inc. raised its stake in Johnson & Johnson by 333.3% during the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares in the last quarter. First Bank & Trust raised its stake in Johnson & Johnson by 69.6% during the 2nd quarter. First Bank & Trust now owns 380 shares of the company’s stock valued at $67,000 after acquiring an additional 156 shares in the last quarter. Finally, Heritage Wealth Management LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at $84,000. Institutional investors and hedge funds own 67.94% of the company’s stock.
Johnson & Johnson Stock Performance
Shares of NYSE JNJ opened at $168.74 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The stock has a market capitalization of $441.17 billion, a price-to-earnings ratio of 23.50, a PEG ratio of 3.28 and a beta of 0.56. The stock’s fifty day simple moving average is $176.14 and its 200 day simple moving average is $171.30. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69.
Johnson & Johnson Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.68%. Johnson & Johnson’s dividend payout ratio is 62.95%.
In other news, VP Peter Fasolo sold 29,275 shares of Johnson & Johnson stock in a transaction on Monday, October 24th. The stock was sold at an average price of $171.36, for a total transaction of $5,016,564.00. Following the transaction, the vice president now owns 114,676 shares in the company, valued at $19,650,879.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 76,923 shares of the business’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the transaction, the executive vice president now owns 126,456 shares in the company, valued at $22,354,891.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Peter Fasolo sold 29,275 shares of the business’s stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $171.36, for a total value of $5,016,564.00. Following the completion of the transaction, the vice president now owns 114,676 shares in the company, valued at approximately $19,650,879.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 277,886 shares of company stock worth $48,550,549. 0.35% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on JNJ shares. Morgan Stanley cut their target price on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 6th. Barclays initiated coverage on Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price objective on the stock. Bank of America dropped their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a research note on Friday, October 14th. Citigroup boosted their price objective on Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, December 12th. Finally, StockNews.com initiated coverage on Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.75.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.